Vancouver, Canada-based Sierra Oncology Inc. is planning an underwritten public offering of its common stock.
The cancer specialist plans to grant underwriters a 30-day option to buy up to an additional 15% of shares offered.
Sierra plans to use the proceeds to develop its product candidates SRA737 and SRA141 and to fund general corporate purposes.
Jefferies is acting as the sole book-running manager for the offering.
